GlassScriptPhysician profile
Robert N Galbut
NPI 1730295486
$1,345.50
in general payments reported to CMS, 2019-2025
12 companies · $355 in 2025
The $355 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $36.50 · 2021: $32.97 · 2022: $241 · 2023: $233 · 2024: $300 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $888.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $685.64 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Verona Pharma, INC. | $161.38 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals LP | $118.57 | 2019-2025 | Breztri |
| Zimmer Biomet Holdings, INC. | $87.84 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.71 | 2019-2025 | Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $49.07 | 2019-2023 | Glassia |
| Mylan Specialty L.P. | $47.61 | 2020-2024 | Yupelri |
| Pfizer INC. | $45.74 | 2019-2025 | |
| Genzyme Corporation | $25.31 | 2025 | |
| Exact Sciences Corporation | $23.70 | 2023 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $19.19 | 2019 | |
| Emd Serono, INC. | $14.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Galbut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.